FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022753962> ?p ?o ?g. }

• W2022753962 endingPage "60" @default.
• W2022753962 startingPage "59" @default.
• W2022753962 abstract "Allogeneic SCT with both myeloablative and reduced-intensity conditioning (RIC) is effective therapy in acute leukemia. To better define the role of dose intensity in SCT, we retrospectively analyzed SCT outcomes in 356 consecutive adult patients (pts) with MDS/AML (n = 277) and ALL (n = 79) given SCT over an 8-year period in a single institution. The median age was 51 (range, 17–75). The donors were HLA-matched siblings (n = 191), matched unrelated (n = 139) and alternative (n = 26). Pts meeting standard eligibility criteria were routinely given myeloablative conditioning (MAC, Cy/TBI or BuCy, n = 141). Pts non-eligible for MAC were given either RIC (fludarabine and reduced doses of busulfan or melphalan, n = 116) or modified myeloablative conditioning (modMAC, fludarabine with myeloablative doses of busulfan or treosulfan, n = 99). Disease status at SCT was CR1/ CR2 (n = 176), previously untreated or untreated relapse (n = 63) and chemo-refractory (n = 117). With a median follow-up of 30 months (range 1–103), 159 pts are alive and 197 died; 75 of treatment-related causes and 122 of relapse. The estimated 5-yr overall survival (OS) in this relatively high-risk pt group was 34% (95%CI, 27–41). The status of disease at SCT was the most important factor predicting OS; 48, 31 and 16% for pts in CR, untreated or chemo-refractory leukemia, respectively (p<0.001). Multivariable analysis (MVA) identified SCT not in CR, SCT from unrelated and alternative donors as adverse prognostic signs with hazard ratios (HR) of 2.7, 1.5, and 2.2, respectively. The conditioning regimen used was not a significant factor in the whole pt group with 5-yr OS of 38, 35 and 31% after MAC, modMAC and RIC, respectively (p = NS). However, RIC was associated with reduced OS in 2 subgroups. Among pts with MDS/AML given SCT not in CR, 5-yr OS was 34, 24 and 13% after MAC, modMAC and RIC, respectively (p = 0.03) with HR of 1.6 for RIC in MVA. In the group of ALL pts, MVA identified RIC and SCT not in CR1 as adverse prognostic signs with HR of 2.0 (p = 0.04) and 2.0 (p = 0.03), respectively. In conclusion, MAC should still be considered the standard of care for SCT in acute leukemia in eligible pts. RIC is associated with inferior outcome in pts with ALL and pts not in CR at SCT. Randomized studies are needed to determine the role of RIC in MDS/AML pts in CR at SCT. The novel modMAC regimens are relatively well tolerated even in pts not eligible for MAC and may be more effective than standard RIC in refractory disease." @default.
• W2022753962 created "2016-06-24" @default.
• W2022753962 creator A5000660923 @default.
• W2022753962 creator A5020301140 @default.
• W2022753962 creator A5020369336 @default.
• W2022753962 creator A5045152818 @default.
• W2022753962 creator A5058925624 @default.
• W2022753962 creator A5081737366 @default.
• W2022753962 date "2009-02-01" @default.
• W2022753962 modified "2023-09-26" @default.
• W2022753962 title "Conditioning Regimens Prior to Allogeneic Stem-Cell Transplantation (SCT) In Acute Leukemia: The Role Of Dose Intensity" @default.
• W2022753962 doi "https://doi.org/10.1016/j.bbmt.2008.12.185" @default.
• W2022753962 hasPublicationYear "2009" @default.
• W2022753962 type Work @default.
• W2022753962 sameAs 2022753962 @default.
• W2022753962 citedByCount "0" @default.
• W2022753962 crossrefType "journal-article" @default.
• W2022753962 hasAuthorship W2022753962A5000660923 @default.
• W2022753962 hasAuthorship W2022753962A5020301140 @default.
• W2022753962 hasAuthorship W2022753962A5020369336 @default.
• W2022753962 hasAuthorship W2022753962A5045152818 @default.
• W2022753962 hasAuthorship W2022753962A5058925624 @default.
• W2022753962 hasAuthorship W2022753962A5081737366 @default.
• W2022753962 hasBestOaLocation W20227539621 @default.
• W2022753962 hasConcept C121332964 @default.
• W2022753962 hasConcept C126322002 @default.
• W2022753962 hasConcept C141071460 @default.
• W2022753962 hasConcept C142424586 @default.
• W2022753962 hasConcept C143998085 @default.
• W2022753962 hasConcept C207103383 @default.
• W2022753962 hasConcept C2776694085 @default.
• W2022753962 hasConcept C2776755627 @default.
• W2022753962 hasConcept C2777408962 @default.
• W2022753962 hasConcept C2778684742 @default.
• W2022753962 hasConcept C2779015954 @default.
• W2022753962 hasConcept C2779178397 @default.
• W2022753962 hasConcept C2779263901 @default.
• W2022753962 hasConcept C2780611847 @default.
• W2022753962 hasConcept C2911091166 @default.
• W2022753962 hasConcept C44249647 @default.
• W2022753962 hasConcept C71924100 @default.
• W2022753962 hasConcept C87355193 @default.
• W2022753962 hasConcept C90924648 @default.
• W2022753962 hasConceptScore W2022753962C121332964 @default.
• W2022753962 hasConceptScore W2022753962C126322002 @default.
• W2022753962 hasConceptScore W2022753962C141071460 @default.
• W2022753962 hasConceptScore W2022753962C142424586 @default.
• W2022753962 hasConceptScore W2022753962C143998085 @default.
• W2022753962 hasConceptScore W2022753962C207103383 @default.
• W2022753962 hasConceptScore W2022753962C2776694085 @default.
• W2022753962 hasConceptScore W2022753962C2776755627 @default.
• W2022753962 hasConceptScore W2022753962C2777408962 @default.
• W2022753962 hasConceptScore W2022753962C2778684742 @default.
• W2022753962 hasConceptScore W2022753962C2779015954 @default.
• W2022753962 hasConceptScore W2022753962C2779178397 @default.
• W2022753962 hasConceptScore W2022753962C2779263901 @default.
• W2022753962 hasConceptScore W2022753962C2780611847 @default.
• W2022753962 hasConceptScore W2022753962C2911091166 @default.
• W2022753962 hasConceptScore W2022753962C44249647 @default.
• W2022753962 hasConceptScore W2022753962C71924100 @default.
• W2022753962 hasConceptScore W2022753962C87355193 @default.
• W2022753962 hasConceptScore W2022753962C90924648 @default.
• W2022753962 hasIssue "2" @default.
• W2022753962 hasLocation W20227539621 @default.
• W2022753962 hasOpenAccess W2022753962 @default.
• W2022753962 hasPrimaryLocation W20227539621 @default.
• W2022753962 hasRelatedWork W1984641455 @default.
• W2022753962 hasRelatedWork W2100630425 @default.
• W2022753962 hasRelatedWork W2237296780 @default.
• W2022753962 hasRelatedWork W2252295961 @default.
• W2022753962 hasRelatedWork W2561452209 @default.
• W2022753962 hasRelatedWork W2583985383 @default.
• W2022753962 hasRelatedWork W2620956092 @default.
• W2022753962 hasRelatedWork W2743113491 @default.
• W2022753962 hasRelatedWork W2918037464 @default.
• W2022753962 hasRelatedWork W3002257611 @default.
• W2022753962 hasVolume "15" @default.
• W2022753962 isParatext "false" @default.
• W2022753962 isRetracted "false" @default.
• W2022753962 magId "2022753962" @default.
• W2022753962 workType "article" @default.